CDAK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 apr 2024 @ 22:00):

Stats
Dagens volum	14.21M
Gjennomsnittsvolum	0.00
Markedsverdi	2.83M
EPS	$0 ( 2023-11-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0210 (105.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-30	Howze Yalonda	Sell	1 628	Common Stock
2023-03-29	Sathyanarayanan Sriram	Sell	11 762	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	7 432	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	1 932	Common Stock
2023-03-28	Bain Linda	Sell	13 412	Common Stock

INSIDER POWER
92.96
Last 100 transactions
Buy: 14 044 661 \| Sell: 316 076

Volum Korrelasjon

Lang: -0.25 (neutral)

Kort: 0.79 (moderate)

Signal:(35.08) Neutral

Codiak BioSciences, Inc. Korrelasjon

10 Mest positive korrelasjoner
DTEA	0.934
PAYO	0.888
NAII	0.886
MKTX	0.884
NLSP	0.883
PMTS	0.883
OBNK	0.88
PRAA	0.879
THMA	0.877
VEDU	0.876

10 Mest negative korrelasjoner
RMRM	-0.947
CVLT	-0.945
EVLV	-0.941
APYX	-0.937
FLXN	-0.937
CELH	-0.935
APLD	-0.929
PRSR	-0.927
QTRX	-0.926
CNCE	-0.925

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Codiak BioSciences, Inc. Korrelasjon - Valuta/Råvare

0.63
( weak )

0.73
( moderate )

0.00
( neutral )

0.70
( moderate )

0.07
( neutral )

-0.77
( moderate negative )

Codiak BioSciences, Inc. Økonomi

Annual	2021
Omsetning:	$22.94M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.664

FY	2021
Omsetning:	$22.94M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.664

FY	2020
Omsetning:	$2.92M
Bruttogevinst:	$2 915.00 (0.10 %)
EPS:	$-16.18

FY	2019
Omsetning:	$388 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-5.96

Financial Reports:

No articles found.

Codiak BioSciences, Inc.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.